A Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken at Bedtime in Subjects With Military-Related PTSD and Related Conditions (Protocol No. TNX-CY-P201) -"AtEase STUDY"

Trial Profile

A Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken at Bedtime in Subjects With Military-Related PTSD and Related Conditions (Protocol No. TNX-CY-P201) -"AtEase STUDY"

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Acronyms AtEase
  • Sponsors Tonix Pharmaceuticals Inc
  • Most Recent Events

    • 15 Jun 2017 According to a Tonix Pharmaceuticals Holding Corp media release, trial was presented as a poster at the Pathophysiology of Post-Traumatic Stress Disorder: Rethinking Drug Targets summit sponsored by the Department of Defense on June 13, 2017.
    • 30 May 2017 According to a Tonix Pharmaceuticals Holding Corp media release, results of retrospective analyses from the study were presented at the 2017 American Society of Clinical Psychopharmacology Annual Meeting.
    • 30 May 2017 Results of retrospective analysis published in a Tonix Pharmaceuticals Holding Corp media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top